National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.


NCPE Assessment Process Ongoing
Rapid review commissioned 26/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 23/10/2018
Pre-submission consultation with Applicant 19/11/2018
Submission received from applicant 03/01/2019
Current Status HTA assessment ongoing